Q1 Earnings Forecast for Arvinas Issued By Leerink Partnrs

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities research analysts at Leerink Partnrs boosted their Q1 2025 earnings per share estimates for Arvinas in a research report issued on Tuesday, February 11th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.32) per share for the quarter, up from their prior forecast of ($0.50). The consensus estimate for Arvinas' current full-year earnings is ($3.22) per share. Leerink Partnrs also issued estimates for Arvinas' Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($2.66) EPS and FY2027 earnings at $1.77 EPS.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.44. During the same period last year, the business earned ($2.53) earnings per share.

Several other brokerages have also issued reports on ARVN. Wedbush reissued an "outperform" rating and issued a $57.00 price target on shares of Arvinas in a research note on Tuesday, February 11th. Stephens began coverage on Arvinas in a research report on Monday, November 18th. They set an "overweight" rating and a $55.00 target price on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arvinas in a research report on Friday, February 7th. HC Wainwright reaffirmed a "buy" rating and set a $87.00 target price on shares of Arvinas in a research report on Wednesday, December 11th. Finally, Barclays lowered their target price on Arvinas from $48.00 to $32.00 and set an "overweight" rating on the stock in a research report on Monday, February 3rd. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $60.00.

Arvinas Stock Up 1.8 %

ARVN traded up $0.32 during trading on Friday, hitting $18.63. The company's stock had a trading volume of 1,789,729 shares, compared to its average volume of 942,180. Arvinas has a twelve month low of $16.61 and a twelve month high of $51.99. The stock's fifty day moving average price is $18.63 and its 200-day moving average price is $23.05. The firm has a market capitalization of $1.28 billion, a P/E ratio of -3.99 and a beta of 1.88.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. nVerses Capital LLC bought a new position in Arvinas in the 3rd quarter valued at $39,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock valued at $61,000 after purchasing an additional 440 shares during the period. KBC Group NV grew its stake in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after purchasing an additional 1,255 shares during the period. Quantbot Technologies LP grew its stake in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock valued at $108,000 after purchasing an additional 2,601 shares during the period. Finally, Exchange Traded Concepts LLC grew its stake in Arvinas by 37.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $164,000 after purchasing an additional 1,798 shares during the period. Institutional investors own 95.19% of the company's stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.